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1. Introduction 
Asthma is a common chronic inflammatory disease of the respiratory tract characterized by 
episodic exacerbations with a heterogeneous population distribution. The prevalence of 
asthma has increased substantially over the past 5 decades throughout the globe, yet the 
reasons for this increase remain unknown. The disease represents a substantial burden, not 
only in terms of morbidity, mortality and reduced quality of life of patients, but also 
imposing a huge cost on the healthcare facilities in all countries.  
2. Burden of asthma  
Approximately 300 million people worldwide currently have asthma, and its prevalence 
increases by 50% every decade, seeing a rise to 400 million by year 2025 (Braman, 2006; 
Masoli et al., 2004) The increasing number of hospital admissions for asthma, which are 
most pronounced in young children, reflect an increase in severe asthma, poor disease 
management, and poverty. Worldwide, approximately 180,000 deaths annually are 
attributable to asthma. Most asthma deaths occur in those >45 years old and are largely 
preventable, frequently being related to inadequate long-term medical care or delays in 
obtaining medical help during the attack.  
The financial burden on patients with asthma in different western countries ranges from 
$300 to $1,300 per patient per year, disproportionately affecting those with the most severe 
disease. It is the most common chronic disorder in children and adolescents, with more than 
3 million asthma attacks occurring in more than 5% of all children each year. 
Asthma is a cause of concern due to under diagnosis, under investigated, under control and 
non-adherence to treatment (Barreto, 2006, National Institutes of Health, Bethesda, 2006, 
Woolcock, 1989, Bassam, 2012). A recent report from WHO suggests that 50% of patients 
from developed world with chronic diseases do not take their medications as recommended. 
In developing countries, the situation may be even worse when considering together all the 
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issues related with poor access to health care, lack of appropriate diagnosis, and limited 
access to medicines. Poor adherence seriously threatens any effort to tackle such chronic 
illness (WHO, 2003, Horne, 2003). 
Steroids V/S No Steroids in asthma: If ever there was a magic potion that should resolve 
the symptoms of an affliction, it is the use of glucocorticoids in asthma. Since their first 
clinical application, there has been uniform agreement that the anti-inflammatory activities 
of the corticosteroids make them ideal agents to stabilize asthma during all stages of asthma 
symptomatology ranging from chronic persistent phase to acute severe life threatening 
exacerbations. 
Pathophysiology of asthma: Asthmatic inflammatory process results from inappropriate 
immune responses to common environmental antigens in a genetically susceptible 
individual (Wills-Karp 1999). These inappropriate immune responses are orchestrated by a 
subset of CD4+ T helper cells termed T helper 2 (Th2) cells. 
Cytokines play a pivotal role in the development of asthma by regulating the expansion of 
Th2 cells and by mediating many of the Th2 effector functions that underlie the pathogenic 
events of an asthmatic response. Much effort has recently been placed in elucidating the 
pathways used by cytokines to mediate their actions. These studies have revealed that 
cytokine-mediated signals are primarily transduced by the Janus Kinase- Signal Transducer 
and Activator of Transcription (JAK-STAT) signaling cascade (Darnell, 1997). Recent 
advances have shown the important roles of JAK-STAT signaling pathway in the 
pathogenesis of asthma. 
3. JAK-STAT signaling in Th1 and Th2 differentiation: 
The two major subsets of CD4+ T helper cells, Th1 and Th2, secrete mutually distinct 
profiles of cytokines and thereby coordinate different classes of immune response. The 
cytokines IL-12 and IL-4 direct the differentiation of Th1 and Th2 cells, respectively, from 
naive T helper cells. Th1 cells secrete IL-2, IFN-γ, and TNF-β, whereas Th2 cells produce IL-
4, IL-5, IL-6, IL-10, and IL-13.  
Th1 cells are critically involved in the generation of delayed-type hypersensitivity 
responses, whereas Th2 cells can direct B cells to mount strong humoral responses. 
Polarization of immune response toward a Th2 phenotype and when directed against an 
otherwise innocuous environmental antigen result in the pathogenesis of allergic diseases 
like asthma. 
The Th2 cytokines (IL-4, IL-5, and IL-13) control all the major components that characterize 
an inflammatory asthmatic response, including IgE isotype switching, mucus production, 
and the recruitment and activation of eosinophils and have been corroborated by studies in 
humans. The population of Th2 cells is notably expanded in the airways of asthmatic 
subjects, and presence of these cells correlates with airway hyper responsiveness (AHR) and 
airway eosinophilia (Rengarajan et al., 2000, Murphy et al., 2000). 
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IL-4 and IL-12 activate the Jak-Stat signaling cascade discussed elsewhere in this Perspective 
series. In this signaling pathway, binding of a cytokine to its receptor leads to the activation 
of members of the JAK family of receptor associated kinases. These kinases subsequently 
activate, via tyrosine phosphorylation, preexistent cytoplasmic factors termed Stats (signal 
transducer and activator of transcription). Tyrosine phosphorylation allows the Stat proteins 
to dimerize and translocate to the nucleus, where they mediate changes in gene expression 
by binding specific DNA elements. Although both IL-4 and IL-12 follow this basic signaling 
framework, the two cytokines differ in the specific Jak and Stat components that they 
activate (Wurster, A.L. et al 2000). IL-4 stimulates Jak1 and Jak3 to activate Stat6. In contrast, 
interaction of IL-12 with its receptor leads to the activation of Jak2 and Tyk2 and the 
subsequent phosphorylation of Stat4. Activation of Stat6 and Stat4 are thus critical events in 
the signaling cascades of IL-4 and IL-12, respectively. 
Mechanism of Action of steroids: Glucocorticoids (GC’s) are potent anti-inflammatory agents 
and are useful in the treatment of both allergic and idiosyncratic asthma. Although the 
mechanisms of corticosteroid action in asthma are poorly understood, several possible sites of 
action have been proposed which help reverse the pathologic process of bronchial asthma. 
Glucocorticoid receptors (GRs) are specific cytoplasmic transcription factors that mediate 
the biological actions of corticosteroids (Beato M et al 1995). On ligand binding, GR 
translocates into the nucleus and binds to DNA at glucocorticoid response elements (GREs) 
in the promoter region of corticosteroid-responsive genes that induce transcription (Barnes 
PJ & Adcock IM 1998). GR activation may also influence antiinflammatory events by 
nongenomic pathways, forming inhibitory interactions within the nucleus with 
proinflammatory DNA-binding transcription factors, such as activator protein (AP)-1 or 
nuclear factor (NF)–_B, or by recruitment of co-repressors, and thereby repressing the 
actions of these important inflammatory proteins (Karin M. 1998, Ito K et al. 2000). GR 
nuclear translocation is, therefore, essential and necessary for corticosteroid action. 
It has been well investigated that the novel mechanism of GC action is by blocking cytokine 
signaling via the JAK-STAT signaling pathway. Dexamethasone inhibited IL-2-induced 
DNA binding, tyrosine phosphorylation, and nuclear translocation of Stat5 in primary T 
cells. Inhibition of Stat5 correlated with inhibition of expression of IL-2-inducible genes and 
T cell proliferation. The mechanism of inhibition involved suppression of IL-2 receptor and 
Jak3 expression. Signaling by IL-4, IL-7, and IL-15, which use IL-2 receptor components, also 
was inhibited, indicating a block in T cell responses similar to that seen in immunodeficient 
patients lacking the IL-2 receptor gamma chain or Jak3. 
IL-2 signaling also was blocked in patients after treatment with GC’s, suggesting that 
inhibition of cytokine signaling contributes to the clinical efficacy of GC’s. Hence inhibition 
of both cytokine production and Jak- stat signaling contribute to their therapeutic potency 
(Bianchi, 2000). 
Corticosteroids enhance the beta-adrenergic response to relieve the muscle spasm. They also 
act by reversing the mucosal edema, decreasing vascular permeability by vasoconstriction, 
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and inhibiting the release of Leukotrienes (LT) LT-C4 and LT-D4. Corticosteroids reduce the 
mucus secretion by inhibiting the release of secretagogue from macrophages. 
Corticosteroids inhibit the late phase reaction by inhibiting the inflammatory response and 
interfering with chemotaxis due to the inhibition of LT-B4 release. The eosinopenic effect of 
corticosteroids may help to prevent the cytotoxic effect of the major basic protein and other 
inflammatory mediators released from eosinophils. Corticosteroids have no effect on the 
immediate hypersensitivity reaction and have no direct role in bronchial reactivity. By 
blocking the late reaction, they prevent the increased airway reactivity observed with late 
bronchial reactions, all of which aid in the resolution of bronchospasm in asthmatic patients 
(Figure 1) 
 
Figure 1. Mechanism of Action of Corticosteroids in asthma 
Mode of Delivery: All levels of persistent asthma require daily anti-inflammatory treatment 
(with additional doses of oral or intravenous steroid based on the severity of symptoms). 
Inhaled corticosteroids (ICS’s) are the safest and most effective anti-inflammatory treatment 
for patients with persistent asthma of all severity having a significant positive impact on 
outcomes. Although steroids may be given orally or systemically, and numerous non-
steroidal medications are available for treating persistent asthma, ICS’s are the treatment of 
choice considering their risk-benefit and cost-effectiveness ratio. Even when ICS’s are given 
daily over prolong period of time, they have less toxicity than oral or systemic steroids 
administered only occasionally. A wide range of ICS’s are available & the choice depends 
upon the availability, cost, physician and patient’s preference, however it is important to use 
the equipotent doses of various ICS’s while switching over the ICS’s for control of asthma 
(Table-1) 
In cases of acute severe asthma or patients requiring maintenance therapy with steroids for 
chronic persistent asthma intravenous or oral routes are to be preferred, it’s important to 
know the equipotent doses of various type of steroid while starting or switching from one 
form to another or from one steroids to another in order to get the equivalent response and 
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to avoid worsening of symptoms (if underdosing done) or side effects (if overdosing done). 
Table 2 summarizes the equivalent doses of various types of intravenous or oral steroids. 
(http://www.globalrph.com/corticocalc.htm) 
 
Drug 
Low Daily dose 
(µgm) 
 Medicum Daily dose 
(µgm) 
 High Daily dose 
(µgm) 
Beclomethasone 
Dipropionate 
200-500 500-1000 1000-2000 
Budesonide 200-400 400-800 800-1600 
Ciclesonide 80-160 10-320 320-1280 
Flunisolide 500-1000 1000-2000 >2000 
Fluticasone Propionate 100-250 250-500 500-1000 
Mometasone Furoate 200 400 800 
Triamcinolone acetonide 400-1000 1000-2000 >2000 
Table 1. Estimated Equipotent daily doses of all formulations of ICS in adults 
 
Glucocorticoid Approximate Equivalent dose (mg) Half-life(Biologic) hours 
Short-Acting 
Cortisone 25 8-12 
Hydrocortisone 20 8-12 
Intermediate-Acting 
Methylprednisolone 4 18-36 
Prednisolone/ Prednisone 5 18-36 
Triamcinolone 4 18-36 
Long-Acting 
Betamethasone 0.6 - 0.75 36-54 
Dexamethasone 0.75 36-54 
Table 2. Estimated Equipotent daily doses of all formulations of glucocorticoids in adults 
Steroids in Children: ICS are the first-line therapy for persistent asthma in children. Major 
safety concerns of long-term ICS therapy in children include suppression of adrenal 
function and impaired growth and bone development. Dosage, type of inhaler device used, 
patient technique, and characteristics of the individual drug influence systemic effects of 
ICS’s. Systemic side effects can occur when continuous high-dose treatment is required for 
severe asthma or when prescribed dosage is excessive and compliance is unusually good. 
It is very important to know that uncontrolled or severe asthma adversely affects growth 
and final adult height in children & no long-term controlled studies have reported any 
statistically or clinically significant adverse effects on growth of 100-200 µg/ day of ICS’s 
however it may be seen with all ICS’s when a high dose is administered for prolonged 
periods (dose dependent effect). Different age groups seem to differ in their susceptibility to 
the growth-retarding effects of ICS’s, children aged 4 to 10 are more susceptible than 
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adolescents, however Children with asthma treated with ICS’s attain normal adult height 
(predicted from family members) but at a later age( Pedersen, 2001, Agertoft & Pedersen, 
2000,. Sharek, & Bergman 2000). No studies have reported any statistically significant 
increase in risk of fracture in children taking ICS’s. 
Oral or systemic steroids increases the risk of fracture in children with a 32 % increase in 4 
courses ever, however ICS’s are safe in this regard. Controlled longitudinal studies of 2-5 yrs 
duration and several cross sectional studies found no adverse effect of ICS on bone mineral 
density (Agertoft & Pedersen , 1998, Hopp et al., 1995). 
Suppression of Hypothalamic-pituitary-adrenal (HPA) axis: Though differences exist 
between the various ICS’s and inhaler devices, treatment with ICS’s doses of less than 200 
µg budesonide or equivalent daily is normally not associated with any significant 
suppression of the HPA axis in children. At higher doses, small changes in HPA axis 
function can be detected with sensitive methods. The clinical relevance of these findings is 
not known, since there have not been reports of adrenal crisis in clinical trials of ICS’s in 
children. However, adrenal crisis has been reported in children treated with excessively 
high doses of ICS’s (Roux et al., 2003). 
Recent studies confirm that benefits of ICS, properly prescribed and used, clearly outweigh not 
only their potential adverse effects but also the risks associated with poorly controlled asthma. 
Benefits of oral corticosteroids for asthma include reduction in mucus production, chest 
tightness, coughing, and wheezing. Other non-asthma related conditions, such as sinus 
conditions and psoriasis, may also improve due to the anti-inflammatory properties of oral 
steroids.  
Side effects of steroids: Side effects of short-term oral steroids include fluid retention, 
stomach upset, excessive hunger, and blurred vision. Difficulty concentrating, insomnia, 
and mood changes can also occur as a result of taking oral corticosteroids. The systemic 
side-effects of long-term treatment with high doses of ICS’s may include cataracts, 
osteoporosis, easy bruising, and hair loss, Weight gain, an increase in facial hair in women, 
and muscle weakness. Long term use of oral corticosteroids may also increase the risk of 
diabetes, high blood pressure, and certain infections. Systemic effects of inhaled 
glucocorticosteroids are not a problem in adults at doses of ≤ 400 mg budesonide or 
equivalent daily. 
Factors affecting response of ICS’s: Three most important factors that appear to have 
significant impact on the effectiveness of inhaled corticosteroid (ICS) treatment are:  
1.) Patient compliance with inhaled anti-asthma therapy: The term “Compliance” is 
defined as the extent to which a patient’s behavior matches the prescriber’s advice but 
recently it has mostly been superseded by the term adherence, a similar concept but having 
fewer negative connotations from physician/patient relationship point of view (Haynes, 
1979). Adherence is defined as the extent to which the patient’s behavior matches agreed 
recommendations from the prescriber. 
 
Steroids in Asthma: Friend or Foe 575 
The issue of noncompliance is complicated by different patterns of noncompliance and a 
variety of measurements of noncompliance. Cochrane GM 1996 identified several patterns 
of noncompliance, including taking only half of the medications at the prescribed times, 
taking the medication regularly for a period and stopping, and skipping prescribed doses. 
Compliance with preventive therapy such as ICSs whose effect is seen over a period of 
weeks may be less than compliance with drugs that relieve asthma symptoms more rapidly. 
Patient adherence to medication is influenced by a number of factors relating to how the 
individual judges the necessity of their treatment relative to their concerns. These factors can 
be categorized as follows:  
1.  Treatment factors: 
 Dosing schedule too frequent  
 cost / non-availability of medicine 
 Complexity or inconvenience of treatment regimen 
 Need to use proper inhaler technique 
 Discomfort of drug administration (eg, bad taste, dry throat, hoarseness, fungal 
infections) 
 Physician’s Inertia / Attitude/ lack of communication 
 Proper education about the disease not given by physician  
2. Behavioral factors 
 Belief that medication is not really needed ( esp. Controller medicine (ICS) 
 Belief that medication would not work 
 Poor perception of the impact of the disease (symptoms, experience, expectations & 
interpretation of illness ) 
 Fear of adverse effects or dependence/ negative orientation to medicines 
 Steroid phobia 
 Forgetting to take medication 
 Volitional non-adherence: voluntarily not taking medication 
 Non-volitional non-adherence: from failure to take medication properly (e.g. ICS± 
LABA) 
3.  Contextual issues: Past experiences, Cultural issues/ Social beliefs/ Poor pt /View of 
others/ Practical difficulties 
It is important to keep the medication regimen as simple as possible, prioritize 
recommendations, educate the patient regarding disease management, and individualized 
the dosing and schedule of ICS as per patient’s requirment. 
2.) Inhalation technique. The effectiveness of inhaler therapy depends not only on 
compliance, but also on the inhaler technique. Various types of inhaler devices are available 
including trubohaler, discus etc however they can be broadly categorized based on the form 
of drugs used as dry powder inhalers (DPI) and Metered Dose inhalers (MDI). Although 
both types of inhalers are equally effective but While prescribing ICS to patient due 
consideration should be given to the age of the patient, comorbid conditions, coordination 
between the hands & mouth & the educational level of patient, otherwise the inhaled ICS 
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will get deposited in the oropharynx & produce local side effects(such as change in voice, 
Oropharyngeal candidiasis). Use of Spacer with MDI can largely reduce the deposition of 
the ICS in throat & hence avoid local side effects of the steroids. 
3.) Impact of inhalation technique and device on drug deposition in the lungs: For ICSs, 
the efficacy depends on the topical activity of the drug that reaches the target area, whereas 
the adverse events depend both on oral deposition and systemic activity. Systemic activity 
of the drug depends on the amount of the drug absorbed either through the GI tract or 
through the lungs, as well as on the first-pass metabolism for drug absorbed through the GI 
tract. 
The amount of drug delivered to the lungs depends on the inhalation technique,(Dolovich, 
1981, Jackson & Lipworth , 1995) as well as on the type of inhaler used and the fine particle 
size (respirable particle diameter between 1- 4 µm) of the drug. Table -3 shows the 
Estimates of the Lung to Systemic Bioavailability Ratios for different types of ICS’s. 
 
Product 
% Dose Deposited in
the Lungs 
% Dose Reaching the 
Systemic 
Circulation after 
Absorption from the 
Gastrointestinal Tract 
Lung/Systemic 
Bioavailability Ratio 
BDP via CFC 
propellant 
5.5  14.7  0.27 
BDP (non-CFC 
propellant) 
56.1  5.5  0.92 
Budesonide via MDI  15  7.7 0.66 
Budesonide via DPI  30 5.3 0.85 
BDP-beclomethasone dipropionate. CFC-chlorofluorocarbon. MDI-metered-dose inhaler, DPI- dry powder inhaler. 
Table 3. Estimates of the Lung to Systemic Bioavailability Ratios for Inhaled Corticosteroids 
Recent Recommendations about the delivery device for ICS from American College of Chest 
Physicians/American College of Asthma, Allergy, and Immunology states that: 
1. For the treatment of asthma in the outpatient setting, both the MDI with a 
spacer/holding chamber and the DPI are appropriate devices for the delivery of ICS’s. 
2. For outpatient asthma therapy, the selection of an appropriate aerosol delivery device 
for ICS’s includes the patient’s ability to use the device correctly, the preferences of the 
patient for the device, the availability of the drug/device combination, the compatibility 
between the drug and delivery device, the lack of time or skills to properly instruct the 
patient in the use of the device or monitor the appropriate use, the cost of therapy, and 
the potential for reimbursement( Dolovich, 2005). Table -4 summarizes the advantages 
& disadvantages of all the devices available for the delivery of ICS’s 
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Type  Advantages Disadvantages
Small-volume 
jet nebulizer 
(Respiratory 
solution, 
Respules, 
nebules) 
Patient coordination not required 
Effective with tidal breathing 
High dose possible 
Dose modification possible 
Can be used with supplemental 
oxygen 
Can deliver combination therapies 
if compatible 
Lack of portability
Pressurized gas source required 
Lengthy treatment time 
Device cleaning required 
Contamination possible 
Not all medication available in solution 
form 
Does not aerosolize suspensions well 
Device preparation required 
Performance variability 
Expensive when compressor added 
Ultrasonic 
nebulizer 
Patient coordination not required 
High dose possible 
Dose modification possible 
Small dead volume 
small and portable 
Faster delivery than jet nebulizer 
No drug loss during exhalation 
(breath actuated devices) 
Expensive
Need for electric power source  
Contamination possible 
Not all medication available  
Device preparation required before 
treatment 
Does not nebulize suspensions well 
Possible drug degradation airway 
irritation with some drugs
Pressurized 
MDI 
(CFC/ HFA as 
propellant) 
accuhaler, 
Evohalers 
Portable and compact
Treatment time is short 
No drug preparation required 
No contamination of contents 
Dose-dose reproducibility high 
Some can be used with breath 
actuated mouthpiece
Coordination of breathing and device 
actuation needed 
High pharyngeal deposition 
Upper limit to unit dose content 
Remaining doses difficult to determine 
Potential for abuse 
Not all medications available 
Holding 
chamber, 
reverse flow 
spacer, or 
spacer 
(Zerostat, 
Zerostat-v 
spacer) 
Reduces need for coordination 
Reduces pharyngeal deposition 
Inhalation can be more complex for 
some patients 
Can reduce dose available if not used 
properly 
More expensive/Less portable Integral 
actuator devices may alter aerosol 
properties compared to native actuator 
DPI 
(Turbohaler, 
Diskus, 
Rotahaler, 
Handihaler, 
aerolizer) 
Breath-actuated
Less coordination required 
No Propellant required 
Small and portable 
Short treatment time 
Dose counters
Requires moderate to high inspiratory 
flow 
Can result in high pharyngeal 
deposition 
Not all medications available 
CFC-Cloro-fluor-Carbon, HFA- hydro-fluoro-alkane, MDI- Metered dose inhaler, DPI- Dry Powder inhaler 
Table 4. Advantages and Disadvantages of Aerosol-Generating Device or System 
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In short, effective asthma treatment requires a combination of pharmacology and 
psychology. Effective prescribing needs to take account of patients’ beliefs, expectations, 
and adherence behavior. 
Goal of Asthma Management: According to Global Initiative for Asthma (GINA 2010) 
Guidelines issued by the National Heart Lung & Blood institute, the goals for successful 
management of asthma are to: 
 Achieve and maintain control of symptoms 
 Maintain normal activity level including exercise 
 Maintain pulmonary functions as close to normal as possible 
 Prevent asthma exacerbations 
 Avoid side effects from asthma medications 
 Avoid asthma mortality 
Therefore, for successful management of asthma and optimum control of asthma , patients 
should always be assessed to know their status of asthma control , Following classification 
of asthma by level of control is more relevant and useful (Figure 2). 
 
 
 Adopted from Global Initiative for Asthma (GINA 2010) Guidelines 
* Any exacerbation should prompt review of maintenance treatment to ensure that it is adequate. 
† By definition, an exacerbation in any week makes that an uncontrolled asthma week. 
‡ Lung function testing is not reliable for children 5 years and younger. 
Figure 2. Classification of asthma by level of control 
To reach this goal, four interrelated components of therapy are required:  
Component 1: Develop patient/doctor partnership: In order to help in the effective 
management of asthma so that the asthmatic patient can learn how to: avoid risk factors, 
take medications correctly, understand the difference between “controller” and “reliever” 
medications, monitor their status using symptoms and, if relevant Peak expiratory Flow 
(PEF) recognize signs that asthma is worsening and take action, seek medical help as 
appropriate. 
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Component 2: Identify and Reduce Exposure to Risk Factors: To improve control of 
asthma and reduce medication needs, despite physical activity is a common cause of 
asthma symptoms however patients should not avoid exercise. Common strategies for 
avoiding allergens and pollutants include the followings; Stay away from tobacco smoke, 
patients and parents should not smoke, avoid drugs, foods, and additives if they are 
known to cause symptoms, reduce or, preferably, avoid exposure to occupational 
sensitizers. 
Component 3: Assess, Treat, and Monitor Asthma: Each patient is assigned to one of 
five treatment “steps” based on the frequency and severity of symptoms, PFT values and 
the exacerbations. At each treatment step, asthma education, environmental control & 
vaccination are important component of asthma control. Rescue medication should be 
provided for quick relief of symptoms as needed. As the severity of disease increases, 
from Steps 2- 5, patients should be given one or more regular controller medications (ICS 
) in order to keep asthma under control & to avoid the morbidity & mortality related 
with asthma and to prevent the long term consequences of the disease. Regular use of 
ICS has demonstrated high efficiency in reducing asthma symptoms, reducing frequency 
& severity of exacerbations, reducing mortality, improving quality of life, improving 
lung function, decreasing airway hyper-responsiveness & controlling airway 
inflammation. 
Component 4: Managing asthma exacerbations: Exacerbations of asthma are characterized 
by episodes of progressive increase in shortness of breath, cough, wheezing or chest 
tightness, or some combination of these symptoms. Mamgement of asthma exacerbation 
requires close objective monitoring (both clinical and using PEF), repetitive administration 
of rapid-acting inhaled bronchodilators, early introduction of systemic glucocorticosteroids 
and oxygen supplementation. It is very important to use systemic steroids early in case of 
exacerbation in order to control the underlying inflammation earliest possible. GINA 
guidelines have simplified the recognition of severity of acute exacerbation of asthma and 
management in acute care setting base on the severity of symptoms & response to treatment 
(For details: www.ginasthma.org)  
Stepwise approach for asthma Management: GINA guidelines have simplified the 
management of asthma at all stages in stepwise manner starting from rescue medicines to 
regular controller medicine. (Figure 3)  
4. Glucocorticoid resistance 
Although glucocorticoids are highly effective in the control of chronic inflammation or 
immune dysregulation occurring in asthma pts however a small proportion of patients 
displays persistent immune activation and airway inflammation and fail to respond despite 
high doses of oral corticosteroids imposing a big challenge for the physicians. (Barnes, 1995, 
1995, Sze¯er, 1997). This group of patients has been classified as “steroid-resistant”  
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Adopted from Global Initiative for Asthma (GINA 2010) Guidelines 
Figure 3. Stepwise approach for asthma Management 
Steroid resistant asthma: American Thoracic Society (ATS) defined Steroid resistant 
patients as characterized by a pre-bronchodilator Force expiratory volume in 1 sec (FEV1) of 
less than 70% predicted with a maintained bronchodilator response. Steroid resistance is 
defined by administering a course of oral prednisone e.g. 40 mg/d (divided doses) for 7 days 
or preferably 2 wk, and observing the effect on morning pre-bronchodilator FEV1 (Lee, 
1996). If the FEV1 fails to increase by 15% (and 200 ml), the patient is considered steroid 
resistant (Sally et al., 2000). These patients show the typical diurnal variability in peak 
expiratory flow and bronchodilatation with inhaled B-2 agonists. This type of trial can also 
assess the possibility of poor adherence to the maintenance regimen.  
Patients with steroid resistance can be grouped into two broad categories, 
Type 1 steroid resistance: is either immune-mediated or acquired as the result of 
environmental triggers or lifestyle. Clinically, such patients will develop steroid side effects, 
including adrenal gland suppression, osteoporosis, and cushingoid features from 
pharmacologic doses of systemic steroids. This is because there is only one (glucocorticoid 
resistant) GR gene and these patients have steroid resistance only at the level of their 
immune/inflammatory cells (i.e., T cells). The rest of the tissues in their body remain 
sensitive to the deleterious effects of systemic steroids.  
Type 2 steroid resistances: is rare but involves a generalized primary cortisol resistance that 
affects all tissues and is likely associated with a mutation in the GR gene or genes that 
modulate GR function. This form is not associated with the development of steroid’s side 
effects or suppression of morning cortisol levels (Table 5). It is analogous to genetically 
inherited familial cortisol resistance. When patients present with a history of no side effects 
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after high doses of prednisone, it is critical to confirm that they are taking the oral prednisone 
by checking their morning serum cortisol after a course of therapy under strict supervision. 
Such individuals need alternative approaches to control their pulmonary inflammation. 
 
Features Type 1 steroid resistances Type 2 steroid resistances 
AM cortisol levels Suppressed No 
Cushingoid side effects Yes  No 
Cause 
Cytokine induced(May be 
genetic), Allergy, Microbes 
Genetic 
GCR ligand and DNA 
binding affinity 
Reduced Normal 
GCR numbers Normal or High Low 
Reversibility of GCR defect Yes No 
Table 5. Summarizes difference in both Types of steroid resistance 
It is imperative to exclude confounding factors when trying to make the diagnosis of 
steroid-resistant asthma in a patient. These factors include non-adherence with asthma 
medication, inadequate inhalation technique, incorrect diagnosis, unrecognized concomitant 
diagnoses, and ongoing exposure to environmental allergens, abnormal corticosteroid 
pharmacokinetics, and psychosocial disturbances. Low dose methotrexate, cyclosporine, 
Intravenous immunoglobulin, leukotriene antagonists, such as zafirlukast and montelukast 
and Nedocromil sodium has been used in steroid resistant patients with varying success 
rates and with associated side effects. 
5. Clinical features of glucocorticoid-resistant asthma 
Glucocorticoid resistance in asthma was first described in six patients with asthma who did 
not respond clinically to high doses of systemic glucocorticoids and in whom there was also 
a reduced eosinopenic response (Schwartz et al .,1968). Larger groups of patients with 
chronic asthma who were glucocorticoid resistant were subsequently identified (Carmichael 
et al ., 1981). These patients were not Addisonian and did not suffer from the abnormalities 
in sex hormones described in familial glucocorticoid resistance (see below). Plasma cortisol 
and adrenal suppression in response to exogenous cortisol is normal (Lane et al., 1996). 
Complete glucocorticoid resistance in asthma is very rare, but reduced responsiveness is 
more common, so that oral glucocorticoids are needed to control asthma adequately 
(steroid-dependent asthma). 
Mechanisms of glucocorticoid resistance: There may be several mechanisms for resistance 
to the effects of glucocorticoids. Although a family history of asthma is more common in 
patients with GCR than GCS asthma, little is known about its inheritance. It is possible that 
a certain proportion of the population has glucocorticoid resistance which only becomes 
manifest when they develop a severe immunological or immune disease that requires 
glucocorticoid therapy. Resistance to the inflammatory and immune effects of 
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glucocorticoids should be distinguished from the rare familial glucocorticoid resistance, 
where there is an abnormality of glucocorticoid binding to GR. 
Glucocorticoid resistance may be primary (inherited or acquired of unknown cause) or 
secondary due to reduced glucocorticoid responsiveness (glucocorticoids themselves, 
cytokines, b-adrenergic agonists).  
Primary glucocorticoid resistance: There are several possible mechanisms for a reduced 
anti-inflammatory response to glucocorticoids.  
a. Pharmacokinetic abnormalities. 
b. Antibodies to lipocortin-1. 
c. Cellular abnormalities. 
d. Abnormality in GR function. 
e. Interaction between GR and transcription factors. 
Secondary glucocorticoid resistance: various probable mechanisms include: 
a. Down-regulation of GR. 
b. Effects of cytokines. 
c. Effect of B2 agonists. 
6. Factors contributing to corticosteroid resistance 
A variety of factors known to contribute to immune activation and pulmonary disease have 
been found to alter corticosteroid responsiveness (Table 6). 
 
Clinical allergy and allergen exposure 
Infection 
Smoking 
Obesity 
Stress 
Ethnicity 
Low vitamin D level 
Table 6. Factors Contributing to Corticosteroid Insensitivity 
6.1. Allergen exposure 
Allergen exposure in vivo reduces GR binding affinity in PBMCs from atopic asthmatics. In 
vitro treatment with cat allergen of peripheral blood mononuclear cell (PBMC) from cat-
allergic asthmatics was also observed to reduce GR binding affinity and T-cell proliferation 
induced by allergens compared with control antigens. The induction of these GR binding 
abnormalities was found to be IL-2 and IL-4 dependent. 
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6.2. Infection 
Infection is a common trigger for pulmonary disease. An analysis of the T-cell repertoire in 
patients whose asthma was poorly controlled (FEV1 <75% predicted despite use of high-dose 
corticosteroids) revealed that their T cells were activated by a microbial superantigen. To 
determine whether microbial super antigens could alter corticosteroid sensitivity, the 
capacity of corticosteroids to inhibit the activation of T cells from normal subjects with super 
antigens as compared with the mitogen, phytohemagglutinin, was studied. While 
corticosteroids caused a 99% inhibition of phytohemagglutinin-induced PBMC proliferation, 
there was only 19% inhibition of super antigen-induced T-cell proliferation. The mechanism 
by which super antigens induce corticosteroid resistance of human T cells is via activation of 
the Mitogen-Activated protein Kinase Kinase/Extracellular signal-Regulated Kinase (MEKK-
ERK ) pathway (Li et al., 2004, Goleva et al., 2004). Viruses can also alter response in 
corticosteroids. In particular, rhinovirus has been reported to reduce GR nuclear 
translocation and thereby reduce corticosteroid response. 
6.3. Neutrophilia 
The nature of the inflammatory infiltrate will also determine whether the particular 
pulmonary disease being treated is likely to resolve with corticosteroid therapy. Pulmonary 
diseases associated with infiltration of neutrophils are likely to be Steroid resistant. To 
determine the potential mechanism of corticosteroid resistance in neutrophils, Strickland et 
al.,2001 examined relative amounts of GRα and GRβ in freshly isolated neutrophils and 
observed increased GRβ, but not GRα, protein and mRNA expression in neutrophils at 
baseline and after IL-8 exposure (Strickland et al. 2001). High constitutive expression of GR-
β by neutrophils may provide a mechanism by which these cells escape corticosteroid-
induced cell death.  
6.4. Other factors contributing to steroid resistance 
Other factors contributing to steroid resistance include smoking, stress, obesity, ethnicity, 
and vitamin D deficiency. In smokers, oxidative stress results in reduced levels of histone 
deacetylase-2 (Barnes, Adcock, 2009). Stress may induce steroid resistance via multiple 
mechanisms, including the chronic elevation of the stress hormone, cortisol, which 
downregulates expression of the GR (Haczku , Panettieri, 2010). The association of steroid 
resistance with obesity may be related to the systemic inflammation found in this condition, 
leading to chronic elevation of TNF and mitogen-activated protein kinase (MAPK) 
activation that causes GR dysfunction (Sutherland et al., 2008) Black patients with asthma 
have also been found to have reduced steroid responsiveness compared with white 
asthmatics (Federico, 2005), although the reason for this is not known, but it could be due to 
a combination of genetic and environmental factors. 
Several recent studies on asthmatics have now shown that low vitamin D levels are 
associated with increased corticosteroid requirements, and there is a potential role for 
vitamin D in the enhancement of corticosteroid response (Sutherland et al., 2010) 
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7. Management of corticosteroid resistance 
The management of steroid resistant (SR) asthma poses a significant challenge to the 
clinician. Identification of the SR patient early in the course of illness is important to prevent 
tissue remodeling and irreversible changes in lung pathology. Definitions of clinical 
response to steroid therapy will be dictated by the pulmonary disease being treated and 
time frame for improvement of clinical disease before unacceptable steroid side effects 
occur. In the case of asthma, clinical studies have suggested that favorable response to 
inhaled steroids is associated with high levels of exhaled nitric oxide, high bronchodilator 
response, and a low FEV1/FVC ratio prior to treatment (Barnes,2008) 
A systematic, stepwise approach is important for a successful outcome (Leung and Bloom, 
2003). Table 7 lists factors to be considered in the evaluation of patients with a history of 
steroid resistance.  
 
Correct diagnosis 
Comorbid conditions- rhinosinusitis, congestive heart failure, COPD, Gastro Esophageal 
reflex 
Drug adherence 
Drug delivery 
Drug interactions causing enhanced metabolism of steroids 
Alternative anti-inflammatory therapies 
Table 7. Considerations in Treating Steroid Resistance 
Step 1. Complete Evaluation including history, physical examination, pulmonary function 
testing, and appropriate laboratory tests to confirm the diagnosis and rule out 
concomitant medical disorders such as vocal cord dysfunction, Gastroesophageal 
reflux/aspiration, chronic rhinosinusitis, allergic bronchopulmonary aspergillosis, heart 
failure, COPD & broncholitis etc.(Figure 4) 
Step 2. Try to find out psychological & social factors including adherence to therapy and 
take corrective measures for them.  
Step 3. Observe the inhalational technique of patient, reeducate, reinforce about the proper 
technique especially in patients requiring high doses of ICS for severe persistent 
asthma. Spacer devices should be used to maximize ICS dose delivery and reduce 
adverse effects. 
Step 4. Strict environmental control at home, in school, and at work including finding the 
source of allergens & eliminating the same because persistent allergen exposure will 
increase the symptoms of asthma & reduces steroid responsiveness. 
Step 5. Search for concomitant bacterial/ mycobacterial/ fungal infection of the 
tracheobronchial tree especially in patients taking high doses of ICS or chronic oral 
steroids. Chronic colonization with Mycoplasma pneumoniae or Chlamydia pneumoniae, 
can trigger airway inflammation in chronic asthmatics and thus poor responsiveness to 
steroids. 
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Figure 4. Flow diagram to manage steroid resistant asthma 
Step 6. Search for factors affecting lifestyle and steroid responsiveness. Patients with 
Vitamin D deficiency have increased steroid requirements. Other cofactors, including 
obesity, smoking, no or little exposure to sunlight and pigmented skin are well known 
to lower vitamin D levels.  
Step 7. Combination therapy can be used to maximize clinical response. Inhaled long-
acting β2-agonists (LABA) have been found to enhance Glucocorticoid receptor (GR) 
nuclear translocation and reduced corticosteroid requirements. Consider addition of 
other steroid-sparing drugs such as leukotriene modifiers, anticholinergic drugs, 
nidocromil sodium( Marin, 1996) and theophylline.  
Step 8. In very difficult case, studies to identify systemic steroid pharmacokinetics and 
receptors to assess the basis for corticosteroid resistance to determine whether there is 
incomplete corticosteroid absorption, failure to convert corticosteroids to an active 
form, or rapid elimination of steroids (frequently as a result of interactions with other 
medications). Patients with poor absorption of prednisone usually respond well to oral 
liquid steroid preparations. In patients with rapid corticosteroid elimination, a split 
dosing regimen (morning & afternoon) is suggested. 
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Step 9. Consider Steroid sparing anti-inflammatory therapies that would enhance 
corticosteroid action including cyclosporine (Alexander et al., 1992), IV 
Immunoglobulin (Mazer , 1991), methotrexate (Mullarkey et al. 1998, Erzurum et al., 
1991), mycophenolate mofetil, azathioprine, Macrolides, trolendamycin and gold, 
depending on the severity of asthma and the potential of significant side effects. 
Omalizumab (recombinant anti IgE antibody) is useful in patients with primarily 
allergic asthma & with severe persistent allergic rhinitis.  
Further Studies are needed to determine whether cytokine antagonism—TNF-α, IL-2, IL-4, 
or IL-13—could restore steroid responsiveness because such cytokines have been found to 
induce steroid resistance. Vitamin D has recently been demonstrated to induce IL-10-
producing regulatory T cells (Xystrakis et al., 2006) and enhance steroid action, and may 
therefore be steroid sparing( Zhang et al., 2010) 
8. Novel steroids 
Steroids, either systemic or inhaled, are exquisitely active and effective in asthma, but their 
mechanism of action is broad, and concern for toxicity—even with topical steroids—has 
limited their wider use. A variety of approaches are being pursued to maximize local 
activity within the airways and at the same time to minimize systemic absorption and 
toxicity. One approach is development of on-site-activated steroids such as ciclesonide, 
which is a nonhalogenated ICS prodrug that requires endogenous cleavage by esterases for 
activity. Soft steroids are also being developed; these have improved local, topical selectivity 
and have much less steroid effect outside the target area. They may be inactivated by 
esterases or other enzymes (for example a lactone–glucocorticosteroid conjugate).  
Dissociated glucocorticoids: The recognition that most of the anti-inflammatory effects of 
glucocorticoids are mediated by repression of transcription factors (transrepression), 
whereas the endocrine and metabolic effects of steroids are likely to be mediated via 
glucocorticoid response element binding (transactivation) has led to a search for novel 
corticosteroids that selectively transrepress, thus reducing the potential risk of systemic side 
effects. These dissociated steroids which favor monomeric glucocorticoid receptor 
complexes (i.e., they produce transrepression) and avoid dimerization or transactivation, 
which is undesirable in asthma would make the treatment of asthma more effective without 
the current fear of steroid’s side effects. Agents from each of these categories are undergoing 
clinical trials.  
Steroid sparing : The combination of long acting beta agonist (LABA) with inhaled 
corticosteroid (ICS) is used frequently in asthma and a benefit from adding LABA to ICS has 
been described. One review compared reduced dose (mean 60% reduction in inhaled 
steroid) ICS/LABA combination to either a fixed moderate/high dose ICS or a 
reduced/tapering ICS dose. In adults with asthma, who use moderate to high maintenance 
doses of ICS, the addition of LABA has an ICS-sparing effect. LABA permit a reduction of 
37% (253 mcg BDP) in subjects on minimum maintenance ICS and up to 60% (300 mcg FP) in 
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subjects on maintenance ICS without deterioration in asthma control. They are most 
effective when combined with ICS, and this combination therapy is the preferred treatment 
when a medium dose of ICS alone fails to achieve control of asthma (Gibson, 2005). The 
addition of a LABA to a daily regimen of ICS improves symptom scores, decreases 
nocturnal symptoms, improves lung function, decreases the use of relief medication, 
reduces the number of exacerbations and achieves clinical control of asthma in more 
patients, more rapidly, and at a lower dose of ICS, than ICS given alone(Greening,1994, 
Pauwel, 1997). 
Certain case reports have documented tiotropium as a useful steroid sparing agent however 
future clinical trials are warranted that explore the use of tiotropium as a potential ‘steroid-
sparing agent’ in severe refractory asthma (Kapoor, 2009). 
9. Immunomodulator therapy as steroid sparing 
Methotrexate: Methotrexate may have a small steroid sparing effect in adults with asthma 
who are dependent on oral corticosteroids. However, the overall reduction in daily steroid 
use is probably not large enough to reduce steroid-induced adverse effects. This small 
potential to reduce the impact of steroid side-effects is probably insufficient to offset the 
adverse effects of methotrexate (Davies, 1998) 
Azathioprine : Currently there is a clear lack of evidence to support the use of azathioprine 
in the treatment of chronic asthma as a steroid sparing-agent. Large, long-term studies with 
pre-defined steroid reducing protocols are required before recommendations for clinical 
practice can be made (Dean, 2004) 
Cyclosporine: The improvement in asthma with cyclosporin are small and of questionable 
clinical significance. Given the side effects of cyclosporin, the evidence available does not 
recommend routine use of this drug in the treatment of oral corticosteroid dependent 
asthma (Evans, 2001) 
Chloroquine : There is insufficient evidence to support the use of chloroquine as an oral 
steroid-sparing agent in chronic asthma. Further trials should optimise oral steroid dosage 
before addition of the steroid-sparing agent (Dewey, 2003) 
Troleandomycin : There is insufficient evidence to support the use of troleandomycin in the 
treatment of steroid dependent asthma.( Evans ,2001) 
Gold: Gold has limited clinically significanct benefits as steroid sparing agent & given the 
side effects of gold and necessity for monitoring the use of gold as a steroid sparing agent in 
asthma cannot be recommended.(Evans , 2001) 
10. Conclusion 
Inhaled Corticosteroids are the most effective first line of therapeutic intervention to control 
the primary immunologic mechanism of the disease and to avoid the devastating 
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consequences of this disease with resultant cost- effectiveness and risk benefits analysis 
leading to best control of asthma. As far as steroids are concerned, there is over fear of its 
side effects in the patients as well as physicians which has to be removed. It should be make 
clear that steroids are friends of asthma pts if optimally used but if overused it may turned 
out to be foe, hence emphasis should be given on the optimized and appropriate use of 
steroids based on the asthma severity, Hence physicians should try to use the both edges of 
this “double edged sword” for the benefit of patients. 
In addition to pharmacological intervention, emphasis should always be given on the 
patient’s education about asthma including its pathogenesis, medications, inhalation 
technique and strict environmental control on every visit of the patient. Definitively the 
safety issues of the use of 
Steroids in asthma has to be taken in to consideration in order to address the instructions of 
Hippocrates, “first do no harm” in relation to the steroids, however steroids continue to be 
the most potent and the most effective controller medication for asthma, and their use in the 
appropriate clinical setting remains invaluable for the control & management of asthma in 
clinical practice. 
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